Bioatla, Inc.

BioAtla Announces Share Consolidation

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing